JUPITER, FL – October 24, 2018 (ACCESSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will report its financial results for the quarter…
JUPITER, FL – October 16, 2018 GLOBE NEWSWIRE Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that Zacks Small-Cap Research (“Zacks SCR”) has initiated analyst…
JUPITER, FL – September 7, 2018 (GLOBE NEWSWIRE) Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a fully funded proof…
JUPITER, FL – August 9, 2018 (GLOBE NEWSWIRE) Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, announced its financial results for the second quarter and six months ended…
JUPITER, FL – July 26, 2018 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…
Results Highlighted in BioProcess International and the Global Bioprocessing and Bioanalytics Congress 2018
JUPITER, FL – June 18, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales,…
Three new research collaborations
Positive results in our initial glycoengineering modifications of C1 strains
Achieving high levels of productivity for therapeutic proteins
Board approved a reverse stock split subject to shareholder approval
Recognized industry thought leader joins board
New Chief Accounting Officer appointed
$47.7 million of cash, cash equivalents and investment securities at March 31, 2018
JUPITER, FL – April 25, 2018 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…
Dyadic International Announces 2017 Year End Results and Recent Developments
$49.1 million of cash, cash equivalents and investment securities as of December 31, 2017
Successfully executed two funded collaborations in 2017 and signed three new collaborations in 2018
Early data generated from our research programs are showing encouraging results for C1 technology
Settlement with the last remaining defendant in…
JUPITER, FL – March 15, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), today announced that Chief Financial Officer Thomas L. Dubinski will be on a medical leave of absence, effectively immediately. In Mr. Dubinski’s absence, other executive officers will assume many of Mr. Dubinski’s duties while remaining in their current positions. Ping W. Rawson, the Company’s…
JUPITER, FL – March 13, 2018 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the year…
JUPITER, FL – February 27, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic products at commercial scales, today announced that it has entered into a funded proof of concept research collaboration to…
JUPITER, FL – February 7, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic products at commercial scales, today announced that it has entered into a funded proof of concept research collaboration to…
Dyadic International, Inc. Announces Research and Development Collaboration with the Israel Institute for Biological Research (IIBR) to Combat Emerging Diseases & Threats
JUPITER, FL – January 16, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production…
JUPITER, FL – January 3, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on the development and large-scale manufacture of low cost, better performing biologic vaccines and drugs at flexible commercial scales, today announced the appointment of Barry Buckland, Ph.D., to its Board of Directors, effective January 3rd, 2018.
JUPITER, FL – November 9, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended September 30, 2017.
JUPITER, FL – October 26, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
JUPITER, Fla. October 9, 2017, /PRNewswire/ — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales,…
JUPITER, FL – August 16, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (OTCQX: DYAI) (“Dyadic”) announced that its Board of Directors has authorized a new stock repurchase program, under which the Company may repurchase up to $5 million of its outstanding common stock.
Under this new stock repurchase program, Dyadic may repurchase shares in accordance with all applicable securities laws…
JUPITER, FL – August 10, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended June 30, 2017.
JUPITER, FL – August 4, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), announced today the conclusion of formal collaborative research with Danisco US Inc., a unit of DuPont Industrial Biosciences (“Danisco”). The research collaboration was part of the previously announced DuPont Sale Transaction. The research services by Danisco will conclude September 30, 2017.
JUPITER, FL – July 27, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…
JUPITER, FL – July 10, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), announced today that it has entered into a comprehensive series of research and development agreements, including a potential commercialization agreement, with Biotechnology Development for Industry (“BDI Holdings”), a Spanish biotech company, and its subsidiaries – VLP The Vaccines Company, S.L.U. (“VLPbio”), and Biotechnology Developments…
JUPITER, FL – July 6, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), is pleased to announce that it has received approximately $7.4 million from the escrow account established in connection with the sale of assets of Dyadic’s Industrial Technology business to DuPont on December 31, 2015.
The Company intends to use the funds to support its ongoing…
JUPITER, FL – May 25, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), announced today that its Chairman of the Board, Michael P. Tarnok, and its Audit Committee Chair, Jack L. Kaye, have purchased 50,000 and 35,000 shares of Dyadic International, Inc. common stock, respectively, at $1.40 per share on Wednesday, May 24th, 2017. These shares were purchased…
JUPITER, FL – May 11, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying the proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended March 31, 2017.
JUPITER, FL – April 27, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…
Jupiter, FL – April 18, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI) announced that Dyadic’s Vice President of Research and Development, Dr. Ronen Tchelet, will present ”C1-The Journey of More Productive Cell Expression” at PEGS 2017, The Essential Protein Engineering Summit on Thursday, May 4, 2017 from 3:35 pm to 3:50 pm EST at the Seaport…
JUPITER, FL – April 6, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (OTCQX: DYAI) (“Dyadic”), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that Stephen Warner has resigned from the Board of Directors…
JUPITER, FL – March 15, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the year ended December 31, 2016,…
Dyadic International Announces It Has Reached a Settlement With the Last Remaining Defendant Law Firm, Greenberg Traurig, LLP and Greenberg Traurig, P.A., in Its Professional Liability Litigation
JUPITER, Fla., March 2, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (OTCQX:DYAI), today announced that on March 1, 2017 it reached a confidential, mid-seven figure settlement with the last…
JUPITER, FL – March 1, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging its patented and proprietary C1 expression system technology to help speed up the development and production of biologic drugs at flexible commercial scales, announced today that it will report its financial results for the…
JUPITER, FL – February 16, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (OTCQX: DYAI) (“Dyadic”), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced the successful completion of its previously announced stock…
JUPITER, FL – January 13, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic” or the “Company”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that it entered into a…
JUPITER, FL – December 8, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic” or the “Company”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced the results of its special…
JUPITER, FL – November 10, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended September 30, 2016.
JUPITER, FL – October 27, 2016 (GLOBE NEWSWIRE)– Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company announced today that it will report its financial results for the third quarter ending September 30, 2016 after the market closes on Thursday, November 10, 2016 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss…
· Special meeting to be held December 7, 2016 to seek shareholder approval
· Proxy statement filed with the OTC Markets and posted on Dyadic’s website
JUPITER, FL – October 26, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on the development and large scale manufacture of low cost, better performing biologic vaccines and…
JUPITER, FL – September 7, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on the development and large scale manufacture of low cost, better performing biologic vaccines and drugs at flexible commercial scales, today announced they have entered into a research and development agreement to further advance its proprietary C1 fungal strain…
JUPITER, FL – August 16, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on the development and large scale manufacture of low cost, better performing biologic vaccines and drugs at flexible commercial scales, today announced the appointment of Arindam Bose, Ph.D., to its Board of Directors, effective August 15, 2016.
JUPITER, FL – August 11, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focusing on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended June…
JUPITER, FL – August 11, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic” or the “Company”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced the approval by its Board…
JUPITER, FL – August 8, 2016 – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI) announced today the termination of its Proof of Concept, Exclusive Option & Technology Transfer Agreement, dated, as of March 30, 2011 with Sanofi Pasteur (“Sanofi”).
On August 5, 2016, the Company received a 60-day notice from Sanofi, indicating that they have decided to terminate the Proof of…
JUPITER, FL – May 12, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced financial results for the quarter ending March 31,…
JUPITER, FL – April 28, 2016 (GLOBE NEWSWIRE)– Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company announced today that it will report its financial results for the first quarter ending March 31, 2016 after the market close on Thursday, May 12, 2016 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss…
JUPITER, Fla., April 6, 2016, (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), today announced it has reached a confidential settlement with one of the two remaining defendant law firms in its ongoing professional liability litigation.
A confidential settlement in a low seven figure amount was reached with the law firm of Bilzin Sumberg Baena Price & Axelrod LLP…
JUPITER, FL – March 15, 2016 (GLOBE NEWSWIRE)– Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company announced today that it will report its financial results for the year ending December 31, 2015 after the market close on Tuesday, March 29, 2016 and that it will host a conference call that day at 5:00 p.m. Eastern Time to…
JUPITER, FL – March 3, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (OTCQX: DYAI) (“Dyadic”) announced today that in its lawsuit against Defendants Greenberg Traurig, LLP, Greenberg Traurig, P.A. (collectively, “Greenberg Traurig”) and the Estate of Robert I. Schwimmer, who previously represented the Company while an attorney at Greenberg Traurig, and also against Defendant Bilzin Sumberg Baena Price &…
JUPITER, FL – January 19, 2016 (GLOBE NEWSWIRE) – Dyadic International, Inc. (OTCQX: DYAI) (“Dyadic”) announced today that Robert D. Burke, MD has resigned from the Board of Directors of Dyadic (the ‘Board’) and all related board committees to which he served which included the compensation, and nominating committees of the board effective January 18, 2016.
